Neuroendocrine Tumor Treatment Market: Global Industry Analysis and Forecast (2023-2029)


Neuroendocrine Tumor Treatment Market is expected to reach US$ 2.93 Bn. at a CAGR of 10.11 during the forecast period 2029.

Neuroendocrine Tumor Treatment Market Overview:

The improper growth of neoplasms that arise from cells of the numerous endocrine glands and neurological systems causes neuroendocrine tumours. These are commonly called carcinoid tumours because they get infected first in the intestine.Neuroendocrine Tumor Treatment MarketTo know about the Research Methodology :- Request Free Sample Report

Neuroendocrine Tumor Treatment Market Dynamics:

Increasing prevalence of Neuroendocrine Tumor is expected to propel the market growth.

Increased incidences of neuroendocrine tumours (NETs) are predicted to boost demand for treatment options, boosting the market growth during the forecast period. Novel therapeutics and diagnostic products are being developed at a rapid pace in this field. Neurofibromatosis type 1 (NF1), Multiple endocrine neoplasia type 1 (MEN1), multiple endocrine neoplasia type 2 (MEN2), Von Hippel- tuberous sclerosis complex (TSC) and Lindau syndrome (VHL) disease are all increasing the incidence and prevalence of neuroendocrine tumours (NETs) in the United States. Furthermore, according to a study published in the JAMA Oncology Journal in 2017, the survival rate of all neuroendocrine tumour treatments have improved, particularly in the treatment of distant-stage gastrointestinal neuroendocrine tumours and pancreatic neuroendocrine tumours. This is mostly due to the availability of effective medicines and early disease detection.

The market for neuroendocrine tumour treatment is predicted to grow due to the development of new medications. Cancer can be treated in a variety of ways. One of the most popular treatment options for neuroendocrine tumours is targeted therapy. Cancer treatment that uses targeted therapy is quite effective. As a result, targeted NET therapies are predicted to become more popular in the forecast years. Over the forecast period, the market is expected to grow due to an increase in the number of pharmacological approvals for the treatment of neuroendocrine tumours. For example, in January 2018, Novartis Groupe S.A.'s Advanced Accelerator Applications received FDA approval of its new drug application (NDA) for Lutathera for the treatment of Somatostatin receptor positive gastroenteropancreatic neuroendocrine tumours (GEP-NETs), which include foregut, midgut, and hindgut neuroendocrine tumours.

The report has profiled eighteen key players in the market from different regions. However, report has considered all market leaders, followers and new entrants with investors while analyzing the market and estimation the size of the same. Increasing R&D activities in each region are different and focus is given on the regional impact on the cost, availability of advanced technology are analyzed and report has come up with recommendations for future hot spot in APAC region.

Neuroendocrine Tumor Treatment Market Segment Analysis:

The Global Neuroendocrine Tumor Treatment Market is segmented on the basis of Product, Indication and End-users.

Based on Product, the Somatostanin Analogs segment is expected to dominate the global market during the forecast period. Somatostanin Analogs (SSAs) are the most commonly utilized medications to treat neuroendocrine carcinoma because they reduce cancer growth, symptoms, and target biomarkers. Because of the safe treatment procedures provided by SSAs, they account for the biggest revenue share. SSAs are commonly utilized to treat patients who have failed to respond to radiation therapy or surgery. As a result, many SSAs are now in clinical trials and awaiting clearance, and the market is likely to grow rapidly over the forecast period. Tarveda Therapeutics' PEN-221 and Dauntless Pharmaceuticals' DP1038 are two examples. Drugs like Sunitinib and Everolimus are used in targeted therapy. These medications are used as the first line of therapy for neuroendocrine carcinoma since they have less negative effects. Chemotherapy, radiation therapy, surgery, and tyrosine kinase inhibitors are among the additional products available.

Based on Indication, the gastrointestinal segment accounted for the dominant segment in 2021 as NETs are more likely to arise in the GI tract. According to data provided in a Novartis investor presentation in 2015, GI tumours account for 61% of all NETs, with the small intestine tumour being the most common. According to the American Society of Clinical Oncology (ASCO), roughly 8,000 persons in the United States have diagnosed with GI tract-carcinid tumours in 2017. Over the projected period, the rising occurrence of carcinoid tumours in the GI tract is expected to propel the segment forward.

Neuroendocrine Tumor Treatment Market Regional Insights:

North America is expected to dominate the global market throughout the forecast period.

Because of the increased frequency of neuroendocrine illnesses, developed health care infrastructure, strong clinical pipeline, high level of awareness among individuals, and presence of significant market participants, North America dominates the neuroendocrine tumours market. In this area, there are also supporting insurance programmes, such as Medicare, Medicaid, and Tricare, which make neuroendocrine treatment grow during forecast years. For example, Ipsen got FDA clearance for its Somatuline Depot (lanreotide) Injection 120 mg in December 2014, which is approved for the treatment of adult patients with unresectable, well- or moderately-differentiated, locally progressed or metastatic gastroenteropancreatic neuroendocrine tumours (GEP-NETs).

In addition, the European neuroendocrine tumour therapy market is predicted to grow significantly over the forecast period, owing to an increase in product approvals by the European Commission (EC) for marketing in European countries.

The report also helps in understanding Global Neuroendocrine Tumor Treatment Market dynamics, structure by analyzing the market segments and project the Global Neuroendocrine Tumor Treatment Market size. Clear representation of competitive analysis of key players by product, price, financial position, product portfolio, growth strategies, and regional presence in the Global Neuroendocrine Tumor Treatment Market make the report investor’s guide.

Global Neuroendocrine Tumor Treatment Market Scope: Inquire before buying






Global Neuroendocrine Tumor Treatment Market




Report Coverage
Details




Base Year:
2022
Forecast Period:
2023-2029




Historical Data:
2018 to 2022
Market Size in 2022:
US $ 1.49Bn.




Forecast Period 2023 to 2029 CAGR:
10.11%
Market Size in 2029:
US $ 2.93 Bn.




 Segments Covered:
by Product
Somatostatin Analogs (SSAs)
targeted Therapy
Chemotherapy
others




by Type
Lungs
Pancreas
Gastrointestinal
Others




by Application
Hospitals
Clinics
Others






Neuroendocrine Tumor Treatment Market, by Region:

North America (United States, Canada and Mexico)
Europe (UK, France, Germany, Italy, Spain, Sweden, Austria and Rest of Europe)
Asia Pacific (China, South Korea, Japan, India, Australia, Indonesia, Malaysia, Vietnam, Taiwan, Bangladesh, Pakistan and Rest of APAC)
Middle East and Africa (South Africa, GCC, Egypt, Nigeria and Rest of ME&A)
South America (Brazil, Argentina Rest of South America)

Neuroendocrine Tumor Treatment Market Key Players are:

1.Novartis AG
2.Boehringer Ingelheim International GmbH
3.Pfizer, Inc.
4.Ipsen Pharma
5.AVEO Oncology
6.Hutchison MediPharma Limited
7.Progenics Pharmaceuticals
8.F. Hoffmann-La Roche Ltd
9.Bristol-Myers Squibb Company
10.Viatris Inc.
11.Thermo Fisher Scientific Inc.
12.Regeneron Pharmaceuticals, Inc.
13.Sun Pharmaceutical Industries Ltd.
14.Teva Pharmaceutical Industries Ltd.
15.Eli Lilly and Company
16.LUPIN
17.Advanced Accelerator Applications
18.BioSynthema Inc.

Frequently Asked questions

1. What is the market size of the Global Neuroendocrine Tumor Treatment Market in 2022?
Ans. The market size Global Neuroendocrine Tumor Treatment Market in 2022 was US$ 1.49 Billion.

2. What are the different segments of the Global Neuroendocrine Tumor Treatment Market?
Ans. The Global Neuroendocrine Tumor Treatment Market is divided into Product, Application and Type.

3. What is the study period of this market?
Ans. The Global Neuroendocrine Tumor Treatment Market will be studied from 2022 to 2029.

4. Which region is expected to hold the highest Global Neuroendocrine Tumor Treatment Market share?
Ans. The Asia Pacific dominates the market share in the  market.

5. What  is the Forecast Period of Global Neuroendocrine Tumor Treatment Market?
Ans. The Forecast Period of the market is 2023-2029 in the market. 




1.Preface
1.1. Market Definition and Key Research Objectives
1.2. Research Highlights
2. Assumptions and Research Methodology
2.1. Report Assumptions
2.2. Abbreviations
2.3. Research Methodology
2.3.1. Secondary Research
2.3.1.1. Secondary data
2.3.1.2. Secondary Sources
2.3.2. Primary Research
2.3.2.1. Data from Primary Sources
2.3.2.2. Breakdown of Primary Sources
3. Executive Summary: Global Neuroendocrine Tumor Treatment Market Size, by Market Value (US$ Mn)
3.1. Global Market Segmentation
3.2. Global Market Segmentation Share Analysis, 2019
3.2.1. Global
3.2.2. By Region (North America, Europe, Asia Pacific, South America, Middle East Africa)
3.3. Geographical Snapshot of the Neuroendocrine Tumor Treatment Market
3.4. Geographical Snapshot of the Neuroendocrine Tumor Treatment Market, By Manufacturer share
4. Global Neuroendocrine Tumor Treatment Market Overview, 2022-2029
4.1. Market Dynamics
4.1.1. Drivers
4.1.1.1. Global
4.1.1.2. By Region (North America, Europe, Asia Pacific, South America, Middle East Africa)
4.1.2. Restraints
4.1.2.1. Global
4.1.2.2. By Region (North America, Europe, Asia Pacific, South America, Middle East Africa)
4.1.3. Opportunities
4.1.3.1. Global
4.1.3.2. By Region (North America, Europe, Asia Pacific, South America, Middle East Africa)
4.1.4. Challenges
4.1.4.1. Global
4.1.4.2. By Region (North America, Europe, Asia Pacific, South America, Middle East Africa)
4.1.5. Industry Trends and Emerging Technologies
4.1.6. Porters Five Forces Analysisa
4.1.6.1. Threat of New Entrants
4.1.6.2. Bargaining Power of Buyers/Consumers
4.1.6.3. Bargaining Power of Suppliers
4.1.6.4. Threat of Substitute Products
4.1.6.5. Intensity of Competitive Rivalry
4.1.7. Value Chain Analysis
4.1.8. Technological Roadmap
4.1.9. Regulatory landscape
4.1.10. Impact of the Covid-19 Pandemic on the Global Neuroendocrine Tumor Treatment Market
5. Supply Side and Demand Side Indicators
6. Global Neuroendocrine Tumor Treatment Market Analysis and Forecast, 2022-2029
6.1. Global Neuroendocrine Tumor Treatment Market Size & Y-o-Y Growth Analysis.
7. Global Neuroendocrine Tumor Treatment Market Analysis and Forecasts, 2022-2029
7.1. Market Size (Value) Estimates & Forecast By Product, 2022-2029
7.1.1. Somatostatin Analogs (SSAs)
7.1.2. Targeted Therapy
7.1.3. Chemotherapy
7.1.4. Others
7.2. Market Size (Value) Estimates & Forecast By Indication, 2022-2029
7.2.1. Lungs
7.2.2. Pancreas
7.2.3. Gastrointestinal
7.2.4. Others
7.3. Market Size (Value) Estimates & Forecast By End-Users, 2022-2029
7.3.1. Hospitals
7.3.2. Clinics
7.3.3. Others
8. Global Neuroendocrine Tumor Treatment Market Analysis and Forecasts, By Region
8.1. Market Size (Value) Estimates & Forecast By Region, 2022-2029
8.1.1. North America
8.1.2. Europe
8.1.3. Asia-Pacific
8.1.4. Middle East & Africa
8.1.5. South America
9. North America Neuroendocrine Tumor Treatment Market Analysis and Forecasts, 2022-2029
9.1. Market Size (Value) Estimates & Forecast By Product, 2022-2029
9.1.1. Somatostatin Analogs (SSAs)
9.1.2. Targeted Therapy
9.1.3. Chemotherapy
9.1.4. Others
9.2. Market Size (Value) Estimates & Forecast By Indication, 2022-2029
9.2.1. Lungs
9.2.2. Pancreas
9.2.3. Gastrointestinal
9.2.4. Others
9.3. Market Size (Value) Estimates & Forecast By End-Users, 2022-2029
9.3.1. Hospitals
9.3.2. Clinics
9.3.3. Others
10. North America Neuroendocrine Tumor Treatment Market Analysis and Forecasts, By Country
10.1. Market Size (Value) Estimates & Forecast By Country, 2022-2029
10.1.1. US
10.1.2. Canada
10.1.3. Mexico
11. U.S. Neuroendocrine Tumor Treatment Market Analysis and Forecasts, 2022-2029
11.1. Market Size (Value) Estimates & Forecast By Product, 2022-2029
11.2. Market Size (Value) Estimates & Forecast By Indication, 2022-2029
11.3. Market Size (Value) Estimates & Forecast By End-Users, 2022-2029
12. Canada Neuroendocrine Tumor Treatment Market Analysis and Forecasts, 2022-2029
12.1. Market Size (Value) Estimates & Forecast By Product, 2022-2029
12.2. Market Size (Value) Estimates & Forecast By Indication, 2022-2029
12.3. Market Size (Value) Estimates & Forecast By End-Users, 2022-2029
13. Mexico Neuroendocrine Tumor Treatment Market Analysis and Forecasts, 2022-2029
13.1. Market Size (Value) Estimates & Forecast By Product, 2022-2029
13.2. Market Size (Value) Estimates & Forecast By Indication, 2022-2029
13.3. Market Size (Value) Estimates & Forecast By End-Users, 2022-2029
14. Europe Neuroendocrine Tumor Treatment Market Analysis and Forecasts, 2022-2029
14.1. Market Size (Value) Estimates & Forecast By Product, 2022-2029
14.2. Market Size (Value) Estimates & Forecast By Indication, 2022-2029
14.3. Market Size (Value) Estimates & Forecast By End-Users, 2022-2029
15. Europe Neuroendocrine Tumor Treatment Market Analysis and Forecasts, By Country
15.1. Market Size (Value) Estimates & Forecast By Country, 2022-2029
15.1.1. U.K
15.1.2. France
15.1.3. Germany
15.1.4. Italy
15.1.5. Spain
15.1.6. Sweden
15.1.7. CIS Countries
15.1.8. Rest of Europe
16. U.K. Neuroendocrine Tumor Treatment Market Analysis and Forecasts, 2022-2029
16.1. Market Size (Value) Estimates & Forecast By Product, 2022-2029
16.2. Market Size (Value) Estimates & Forecast By Indication, 2022-2029
16.3. Market Size (Value) Estimates & Forecast By End-Users, 2022-2029
17. France Neuroendocrine Tumor Treatment Market Analysis and Forecasts, 2022-2029
17.1. Market Size (Value) Estimates & Forecast By Product, 2022-2029
17.2. Market Size (Value) Estimates & Forecast By Indication, 2022-2029
17.3. Market Size (Value) Estimates & Forecast By End-Users, 2022-2029
18. Germany Neuroendocrine Tumor Treatment Market Analysis and Forecasts, 2022-2029
18.1. Market Size (Value) Estimates & Forecast By Product, 2022-2029
18.2. Market Size (Value) Estimates & Forecast By Indication, 2022-2029
18.3. Market Size (Value) Estimates & Forecast By End-Users, 2022-2029
19. Italy Neuroendocrine Tumor Treatment Market Analysis and Forecasts, 2022-2029
19.1. Market Size (Value) Estimates & Forecast By Product, 2022-2029
19.2. Market Size (Value) Estimates & Forecast By Indication, 2022-2029
19.3. Market Size (Value) Estimates & Forecast By End-Users, 2022-2029
20. Spain Neuroendocrine Tumor Treatment Market Analysis and Forecasts, 2022-2029
20.1. Market Size (Value) Estimates & Forecast By Product, 2022-2029
20.2. Market Size (Value) Estimates & Forecast By Indication, 2022-2029
20.3. Market Size (Value) Estimates & Forecast By End-Users, 2022-2029
21. Sweden Neuroendocrine Tumor Treatment Market Analysis and Forecasts, 2022-2029
21.1. Market Size (Value) Estimates & Forecast By Product, 2022-2029
21.2. Market Size (Value) Estimates & Forecast By Indication, 2022-2029
21.3. Market Size (Value) Estimates & Forecast By End-Users, 2022-2029
22. CIS Countries Neuroendocrine Tumor Treatment Market Analysis and Forecasts, 2022-2029
22.1. Market Size (Value) Estimates & Forecast By Product, 2022-2029
22.2. Market Size (Value) Estimates & Forecast By Indication, 2022-2029
22.3. Market Size (Value) Estimates & Forecast By End-Users, 2022-2029
23. Rest of Europe Neuroendocrine Tumor Treatment Market Analysis and Forecasts, 2022-2029
23.1. Market Size (Value) Estimates & Forecast By Product, 2022-2029
23.2. Market Size (Value) Estimates & Forecast By Indication, 2022-2029
23.3. Market Size (Value) Estimates & Forecast By End-Users, 2022-2029
24. Asia Pacific Neuroendocrine Tumor Treatment Market Analysis and Forecasts, 2022-2029
24.1. Market Size (Value) Estimates & Forecast By Product, 2022-2029
24.2. Market Size (Value) Estimates & Forecast By Indication, 2022-2029
24.3. Market Size (Value) Estimates & Forecast By End-Users, 2022-2029
25. Asia Pacific Neuroendocrine Tumor Treatment Market Analysis and Forecasts, by Country
25.1. Market Size (Value) Estimates & Forecast By Country, 2022-2029
25.1.1. China
25.1.2. India
25.1.3. Japan
25.1.4. South Korea
25.1.5. Australia
25.1.6. ASEAN
25.1.7. Rest of Asia Pacific
26. China Neuroendocrine Tumor Treatment Market Analysis and Forecasts, 2022-2029
26.1. Market Size (Value) Estimates & Forecast By Product, 2022-2029
26.2. Market Size (Value) Estimates & Forecast By Indication, 2022-2029
26.3. Market Size (Value) Estimates & Forecast By End-Users, 2022-2029
27. India Neuroendocrine Tumor Treatment Market Analysis and Forecasts, 2022-2029
27.1. Market Size (Value) Estimates & Forecast By Product, 2022-2029
27.2. Market Size (Value) Estimates & Forecast By Indication, 2022-2029
27.3. Market Size (Value) Estimates & Forecast By End-Users, 2022-2029
28. Japan Neuroendocrine Tumor Treatment Market Analysis and Forecasts, 2022-2029
28.1. Market Size (Value) Estimates & Forecast By Product, 2022-2029
28.2. Market Size (Value) Estimates & Forecast By Indication, 2022-2029
28.3. Market Size (Value) Estimates & Forecast By End-Users, 2022-2029
29. South Korea Neuroendocrine Tumor Treatment Market Analysis and Forecasts, 2022-2029
29.1. Market Size (Value) Estimates & Forecast By Product, 2022-2029
29.2. Market Size (Value) Estimates & Forecast By Indication, 2022-2029
29.3. Market Size (Value) Estimates & Forecast By End-Users, 2022-2029
30. Australia Neuroendocrine Tumor Treatment Market Analysis and Forecasts, 2022-2029
30.1. Market Size (Value) Estimates & Forecast By Product, 2022-2029
30.2. Market Size (Value) Estimates & Forecast By Indication, 2022-2029
30.3. Market Size (Value) Estimates & Forecast By End-Users, 2022-2029
31. ASEAN Neuroendocrine Tumor Treatment Market Analysis and Forecasts, 2022-2029
31.1. Market Size (Value) Estimates & Forecast By Product, 2022-2029
31.2. Market Size (Value) Estimates & Forecast By Indication, 2022-2029
31.3. Market Size (Value) Estimates & Forecast By End-Users, 2022-2029
32. Rest of Asia Pacific Neuroendocrine Tumor Treatment Market Analysis and Forecasts, 2022-2029
32.1. Market Size (Value) Estimates & Forecast By Product, 2022-2029
32.2. Market Size (Value) Estimates & Forecast By Indication, 2022-2029
32.3. Market Size (Value) Estimates & Forecast By End-Users, 2022-2029
33. Middle East Africa Neuroendocrine Tumor Treatment Market Analysis and Forecasts, 2022-2029
33.1. Market Size (Value) Estimates & Forecast By Product, 2022-2029
33.2. Market Size (Value) Estimates & Forecast By Indication, 2022-2029
33.3. Market Size (Value) Estimates & Forecast By End-Users, 2022-2029
34. Middle East Africa Neuroendocrine Tumor Treatment Market Analysis and Forecasts, by Country
34.1. Market Size (Value) Estimates & Forecast by Country, 2022-2029
34.1.1. South Africa
34.1.2. GCC Countries
34.1.3. Egypt
34.1.4. Nigeria
34.1.5. Rest of ME&A
35. South Africa Neuroendocrine Tumor Treatment Market Analysis and Forecasts, 2022-2029
35.1. Market Size (Value) Estimates & Forecast By Product, 2022-2029
35.2. Market Size (Value) Estimates & Forecast By Indication, 2022-2029
35.3. Market Size (Value) Estimates & Forecast By End-Users, 2022-2029
36. GCC Countries Neuroendocrine Tumor Treatment Market Analysis and Forecasts, 2022-2029
36.1. Market Size (Value) Estimates & Forecast By Product, 2022-2029
36.2. Market Size (Value) Estimates & Forecast By Indication, 2022-2029
36.3. Market Size (Value) Estimates & Forecast By End-Users, 2022-2029
37. Egypt Neuroendocrine Tumor Treatment Market Analysis and Forecasts, 2022-2029
37.1. Market Size (Value) Estimates & Forecast By Product, 2022-2029
37.2. Market Size (Value) Estimates & Forecast By Indication, 2022-2029
37.3. Market Size (Value) Estimates & Forecast By End-Users, 2022-2029
38. Nigeria Neuroendocrine Tumor Treatment Market Analysis and Forecasts, 2022-2029
38.1. Market Size (Value) Estimates & Forecast By Product, 2022-2029
38.2. Market Size (Value) Estimates & Forecast By Indication, 2022-2029
38.3. Market Size (Value) Estimates & Forecast By End-Users, 2022-2029
39. Rest of ME&A Neuroendocrine Tumor Treatment Market Analysis and Forecasts, 2022-2029
39.1. Market Size (Value) Estimates & Forecast By Product, 2022-2029
39.2. Market Size (Value) Estimates & Forecast By Indication, 2022-2029
39.3. Market Size (Value) Estimates & Forecast By End-Users, 2022-2029
40. South America Neuroendocrine Tumor Treatment Market Analysis and Forecasts, 2022-2029
40.1. Market Size (Value) Estimates & Forecast By Product, 2022-2029
40.2. Market Size (Value) Estimates & Forecast By Indication, 2022-2029
40.3. Market Size (Value) Estimates & Forecast By End-Users, 2022-2029
41. South America Neuroendocrine Tumor Treatment Market Analysis and Forecasts, by Country
41.1. Market Size (Value) Estimates & Forecast by Country, 2022-2029
41.1.1. Brazil
41.1.2. Argentina
41.1.3. Rest of South America
42. Brazil Neuroendocrine Tumor Treatment Market Analysis and Forecasts, 2022-2029
42.1. Market Size (Value) Estimates & Forecast By Product, 2022-2029
42.2. Market Size (Value) Estimates & Forecast By Indication, 2022-2029
42.3. Market Size (Value) Estimates & Forecast By End-Users, 2022-2029
43. Argentina Neuroendocrine Tumor Treatment Market Analysis and Forecasts, 2022-2029
43.1. Market Size (Value) Estimates & Forecast By Product, 2022-2029
43.2. Market Size (Value) Estimates & Forecast By Indication, 2022-2029
43.3. Market Size (Value) Estimates & Forecast By End-Users, 2022-2029
44. Rest of South America Neuroendocrine Tumor Treatment Market Analysis and Forecasts, 2022-2029
44.1. Market Size (Value) Estimates & Forecast By Product, 2022-2029
44.2. Market Size (Value) Estimates & Forecast By Indication, 2022-2029
44.3. Market Size (Value) Estimates & Forecast By End-Users, 2022-2029
45. Competitive Landscape
45.1. Geographic Footprint of Major Players in the Global Neuroendocrine Tumor Treatment Market
45.2. Competition Matrix
45.2.1. Competitive Benchmarking of Key Players By Price, Presence, Market Share, Applications and R&D Investment
45.2.2. New Product Launches and Product Enhancements
45.2.3. Market Consolidation
45.2.3.1. M&A by Regions, Investment and Verticals
45.2.3.2. M&A, Forward Integration and Backward
Integration
45.2.3.3. Partnership, Joint Ventures and Strategic Alliances/ Sales Agreements
45.3. Company Profile : Key Players
45.3.1. Novartis AG
45.3.1.1. Company Overview
45.3.1.2. Financial Overview
45.3.1.3. Geographic Footprint
45.3.1.4. Product Portfolio
45.3.1.5. Business Strategy
45.3.1.6. Recent Developments
45.3.2. Boehringer Ingelheim International GmbH
45.3.3. Pfizer, Inc.
45.3.4. Ipsen Pharma
45.3.5. AVEO Oncology
45.3.6. Hutchison MediPharma Limited
45.3.7. Progenics Pharmaceuticals
45.3.8. F. Hoffmann-La Roche Ltd
45.3.9. Bristol-Myers Squibb Company
45.3.10. Viatris Inc.
45.3.11. Thermo Fisher Scientific Inc.
45.3.12. Regeneron Pharmaceuticals, Inc.
45.3.13. Sun Pharmaceutical Industries Ltd.
45.3.14. Teva Pharmaceutical Industries Ltd.
45.3.15. Eli Lilly and Company
45.3.16. LUPIN
45.3.17. Advanced Accelerator Applications
45.3.18. BioSynthema Inc.
46. Primary Key Insights
  • INQUIRE BEFORE BUYING